In:
British Journal of Clinical Pharmacology, Wiley, Vol. 87, No. 12 ( 2021-12), p. 4823-4830
Abstract:
To assess association between quetiapine treatment and risk of new‐onset hypothyroidism in schizophrenia patients. Methods We conducted a retrospective cohort study in a tertiary hospital in China between January 2016 and December 2018. Schizophrenia patients with normal thyroid tests at admission were included. Hypothyroidism, which was defined as thyroid‐stimulating hormone 〉 4.20 mU/L and free thyroxine 〈 12.00 pmol/L, or on L‐thyroxine prescriptions, was the outcome measure, and quetiapine treatment between admission and subsequent thyroid test was the exposure measure of this study. Adjusted relative risks and 95% confidence intervals were used to assess the independent association of quetiapine treatment with risk of new‐onset hypothyroidism. The dose–response association was further analysed by 3 quetiapine doses: low (≤ 〈 =0.2 g/d), medium (0.2–0.6 g/d), and high ( 〉 0.6 g/d). Results A total of 2022 eligible patients were included in the final analysis. Sixty patients (15.0%) in the quetiapine group developed hypothyroidism, while 56 patients (3.5%) in the nonquetiapine group developed hypothyroidism. Relative risk (95% confidence interval) of developing hypothyroidism for quetiapine use was 4.01 (2.86–5.64) after adjusting for several potential confounding factors. A strong dose–response association between quetiapine use and risk of developing hypothyroidism was observed: adjusted relative risks (95% confidence intervals) were 1.00 (0.25–2.59), 4.22 (2.80–6.25) and 5.62 (3.66–8.38), respectively, for low‐, medium‐ and high‐dose quetiapine, as compared with no quetiapine. Conclusion Acute phase quetiapine treatment for schizophrenia patients was strongly associated with increased risk of developing new‐onset hypothyroidism, with a clear dose–response association.
Type of Medium:
Online Resource
ISSN:
0306-5251
,
1365-2125
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
1498142-7
SSG:
15,3
Permalink
